Hindsight suggests that this controversy may have been limited if the original phase III clinical trials of interferon betas in MS universally incorporated validated depression rating scales, rather than relying on physician-reported adverse outcomes to assess risk of depression and suicidality [34]. Here, IFNB1 is linked to depressive symptom measurement.